EUR 20m to identify new targets and develop first in class drugs
Category: News
Companies collaborate to launch walk-in pain clinic
CellVoyant’s platform combines AI with live cell imaging
Researchers compared 20 years of antibiotic use on E. coli in the UK and Norway
If successful, the new test could see routine screening introduced in the NHS
The diagnostic system can deliver particles to the lungs via aerosol or a nebuliser
In 2022, around 8% of patients survived 30 days after a cardiac arrest
The £30m ADVANCE study is the most extensive study into liver disease worldwide
The partnership will advance VTP-500 from early development to phase 2 clinical trials
Both aim to advance the use of AI-powered cell analysis for cancer, stem cell and cell therapies